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Abstract
Objectives Decision analytic modelling is essential in
performing cost-effectiveness analyses (CEAs) of inter-
ventions in cardiovascular disease (CVD). However,
modelling inherently poses challenges that need to be dealt
with since models always represent a simplification of
reality. The aim of this study was to identify and explore
the challenges in modelling CVD interventions.
Methods A document analysis was performed of 40
model-based CEAs of CVD interventions published in
high-impact journals. We analysed the systematically
selected papers to identify challenges per type of inter-
vention (test, non-drug, drug, disease management pro-
gramme, and public health intervention), and a
questionnaire was sent to the corresponding authors to
obtain a more thorough overview. Ideas for possible solu-
tions for the challenges were based on the papers,
responses, modelling guidelines, and other sources.
Results The systematic literature search identified 1,720
potentially relevant articles. Forty authors were identified
after screening the most recent 294 papers. Besides the
challenge of lack of data, the challenges encountered in the
review suggest that it was difficult to obtain a sufficiently
valid and accurate cost-effectiveness estimate, mainly due
to lack of data or extrapolating from intermediate out-
comes. Despite the low response rate of the questionnaire,
it confirmed our results.
Conclusions This combination of a review and a survey
showed examples of CVD modelling challenges found in
studies published in high-impact journals. Modelling
guidelines do not provide sufficient guidance in resolving
all challenges. Some of the reported challenges are specific
to the type of intervention and disease, while some are
independent of intervention and disease.
Key Points for Decision Makers
In the field of cardiovascular disease (CVD),
modelling methods in economic evaluations come
with challenges. Some of the reported challenges are
specific to the type of intervention, but most
challenges are present in all types of CVD
interventions.
Modelling guidelines do not provide sufficient
assistance in resolving all challenges in economic
evaluations in CVD. In addition, many challenges
require unique solutions. Other sources are proposed
but further research is still needed since some
challenges are still unsolved.
The main challenges that are present in modelling
the cost effectiveness of cardiovascular interventions
are lack of data and extrapolation of intermediate or
surrogate outcomes.
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1 Introduction
Decision analytic modelling when performing economic
evaluations of interventions in cardiovascular disease
(CVD) is challenging. For example, modelling is necessary
if extrapolation of short- or intermediate-term results to
long-term outcomes is required and numerous strategies
need to be evaluated without direct evidence. Thus, mod-
elling inherently poses challenges that need to be dealt with
since models always represent a simplification of reality.
The presence of challenges could be dependent on the type
of intervention or the phase of disease in which the inter-
vention would be used.
There are several ways to deal with the challenges in
obtaining an accurate, precise and valid estimate of the
cost effectiveness. The International Society for Phar-
macoeconomics and Outcomes Research (ISPOR) and the
Society for Medical Decision Making (SMDM) have
recently published a series of recommendations for best
practice in performing cost-effectiveness analyses (CEAs)
based on a model [1–7]. These recommendations suggest
some practical solutions to present challenges in model-
ling. However, they are not specific for any type of dis-
ease or intervention and therefore this review aims to
identify and analyse challenges (e.g. multiple indications)
in modelling the cost effectiveness of CVD interventions
that currently exist in the field. Furthermore, we present
ways to address the challenges based on current economic
modelling guidelines and the opinions of experts from the
field.
2 Methods
In order to identify current challenges in the field of CVD,
a document analysis was performed of model-based CEAs
of CVD interventions that were recently published (since
January 2009) in disease-specific, health economical and
general medical journals. In addition, a questionnaire was
sent to the corresponding authors of the selected papers to
obtain a more thorough overview of current CVD model-
ling challenges.
2.1 Selection
To select systematically relevant papers, we used a search
string that contained both cost-effectiveness terms, based
on the validated National Health Service Economic Eval-
uation Database (NHSEED) cost-effectiveness filter [8],
and a disease-specific Medical Subject Heading (MeSH)
term (‘cardiovascular disease’). The search was performed
on 8 May 2013. We assumed that the papers published in
journals with a relatively high impact factor are more
susceptible to complicated challenges. Therefore, we lim-
ited the search results to 12 relatively high-impact factor
journals in three categories: cardiovascular medicine,
general medicine and health economics/health technology
assessment (HTA). To select these 12 journals we sorted all
possible journals per category on impact factor, based on
Journal Citation Reports [9], and included the four
highest ranked journals that also published sufficient car-
diovascular CEAs. The following journals were selected in
the cardiovascular medicine category: Circulation, Euro-
pean Heart Journal, Journal of the American College of
Cardiology, and International Journal of Cardiology; in
the general medicine category: The Lancet, New England
Journal of Medicine, The Journal of the American Medical
Association, and Annals of Internal Medicine; and in the
health economical category: Value in Health, Pharmaco-
Economics, Health Technology Assessment, and Medical
Decision Making.
We sorted the search results (via Ovid MEDLINE) of
the 12 journals on entry date, and selected the most recent
CEAs or methodological papers presenting results, both
based on modelling methods and evaluating a CVD-related
intervention, until we reached a convenience sample of 40
unique corresponding authors. Authors were selected if
they met the following inclusion criteria: they should have
evaluated a CVD intervention using modelling, and could
only be included once as a corresponding author. The most
recent publication of authors who met the inclusion criteria
was included.
2.2 Document Analysis
Using the 40 publications, we extracted CVD modelling
challenges explicitly mentioned in the Methods and Dis-
cussion sections of the papers, and determined the fre-
quency of these challenges over all papers. Before data
extraction, a list with challenges was created to identify
possible challenges that were present in the studies. These
challenges were based on our own experience and that of
five other researchers with sufficient experience
(3–15 years) in performing model-based CEAs. A chal-
lenge was added to the list when it was described in the
paper but not included in the existing list. For each paper,
two reviewers (LB and WR or JS) identified the challenges
described in the Methods and Discussion sections. To be
complete, we included the identified challenges of both
reviewers after we carefully considered both sets of results.
Challenges were initially analysed by type of intervention,
although it is likely that challenges are not specific for one
type of intervention and therefore present in several inter-
ventions. Interventions were categorized into tests (e.g.
screening, diagnostic), non-drug interventions (e.g. surgi-
cally or non-diagnostic devices), drug interventions,
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disease management programmes (DMPs) and public
health interventions.
2.3 Questionnaire
To supplement our literature review, we sent a question-
naire (see electronic supplementary material) by e-mail to
the corresponding authors of the 40 papers to identify
challenges that were not described in the papers and to
estimate the importance of the challenges. The same five
modelling experts tested a pilot version of the question-
naire and indicated new challenges that were not previ-
ously identified. The first part of the questionnaire
focussed on the solved and unsolved challenges that
authors faced while creating and using the model used to
perform their analyses. Authors were asked to provide
data requirement and modelling challenges, and were also
asked to provide their source of inspiration if they man-
aged to solve the specific challenge. The second part of
the questionnaire focussed on the challenges that the
respondent may have experienced during any CEA mod-
elling of a CVD intervention. The list used for the
document analysis was also the basis for the question-
naire. Respondents were asked to indicate how often the
challenge had occurred in model-based CVD intervention
CEAs conducted by the respondent and how much impact
it could have had on the incremental cost-effectiveness
ratio (ICER).
2.4 Analysis
The challenges brought forward by the corresponding
authors and identified in the literature review were ana-
lysed. We then examined ways to address them based on
the current modelling guidelines [1–7], other literature, and
the solutions provided by the authors.
3 Results
3.1 Selection
The systematic literature search identified 1,720 potentially
relevant publications. In order to reach the target of 40
Fig. 1 Flowchart of selected papers. One study investigated two
types of interventions (drug and non-drug interventions) [56].
Modelling; cost effectiveness; cardiovascular disease; challenges;
review; survey; stents; pharmaceuticals; diagnostic test; public health.
DMP disease management programme
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relevant papers with unique corresponding authors, we read
the title, abstract and full paper of 294 publications in case
the title and abstract were non-conclusive (Fig. 1). Table 1
provides an overview of the publications written by these
authors. Most (49 %) of the publications involved CEAs of
tests and drugs; analyses of non-drug interventions, DMPs
and public health interventions were less common. Health
economics journals accounted for approximately half of the
publications included in this study.
3.2 Challenges
Table 2 presents the presence and frequency of each
challenge in each type of intervention and provides ways to
address them. Furthermore, papers that have presented a
solution for a specific challenge are also identified in
Table 2.
3.2.1 Data Requirement Challenges
Challenges such as lack of data (e.g. effectiveness, costs,
adverse events or parameter distributions) and difficulties
in evidence synthesis are usually addressed by performing
sensitivity analyses which show the impact on the out-
comes. Univariate or multivariate sensitivity analyses,
scenario analyses or probabilistic sensitivity analyses are
often used in addressing data requirement challenges.
Furthermore, it is important to recognize the problem of
publication bias when a meta-analysis is performed to
estimate the effectiveness of an intervention. Trial regis-
tries (e.g. ClinicalTrials.gov) can be searched to identify
clinical trials that have not published their results, to reduce
the risk of bias from selective publication. Furthermore,
funnel plots can be used to identify if publication bias
exists [10]. When publication bias is an issue then it could
be useful to adjust for this in the meta-analysis [11].
3.2.2 Structural Uncertainty
Besides parameter uncertainty, our document analysis
showed that modelling studies often encountered structural
uncertainties. This means that it was difficult to include or
consider (1) all relevant comparators; (2) all relevant dis-
ease states or events; and (3) a sufficient time horizon to
capture all relevant differences in costs and consequences.
Often, not all relevant comparators are included in the
model due to data requirements, as could be seen in the
study performed by Magnuson et al. [12], which estimated
the cost effectiveness of drug-eluting stents compared with
coronary artery bypass based on the Future Revasculari-
zation Evaluation in Patients with Diabetes Mellitus:
Optimal Management of Multivessel Disease (FREEDOM)
trial. The trial did not include the second generation of
drug-eluting stents, which meant that the authors were
Table 1 Characteristics of the studies included in the literature review
Frequency Intervention strategya
Test Drug Non-drug DMP Public health intervention
N % N % N % N % N % Total
Generic journals 1 17 1 17 0 0 0 0 4 67 6
The Lancet 1 50 1 50 2
New England Journal of Medicine 1 100 1
Annals of Internal Medicine 1 33 2 67 3
Journal of the American Medical Association 0
Cardiovascular disease journals 5 33 4 27 4 27 0 0 2 13 15
European Heart Journal 1 100 1
Circulation 3 43 2 29 1 14 1 14 7
Journal of the American College of Cardiology 2 50 1 25 1 25 4
International Journal of Cardiology 2 67 1 33 3
Economic evaluation journals 5 25 8 40 5 25 1 5 1 5 20
Health Technology Assessment 1 33 1 33 1 33 3
Medical Decision Making 1 100 1
Value in Health 3 21 6 43 4 29 1 7 14
PharmacoEconomics 1 50 1 50 2
Total 11 27 13 32 9 22 1 2 7 17 41
DMP disease management programme
a One study investigated two types of interventions (drug and non-drug interventions) [56]
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unable to evaluate stents that were available during the
trial. When direct evidence between comparators is lacking
then mixed treatment comparison or network meta-analysis
could be a solution. Recently, seven tutorial papers were
published on evidence synthesis methods for decision
making, including network meta-analysis [13–19]. Stettler
et al. [20] compared the safety and effectiveness of bare-
metal stents and drug-eluting stents by means of a network
Table 2 Frequencies of challenges per type of interventions
Test
intervention
(N = 11)
Non-drug
intervention
(N = 9)
Drug
intervention
(N = 13)
DMP
(N = 1)
Public
health
intervention
(N = 7)
Total
(N = 41b)
Methodological
paper
Example
paper
N % N % N % N % N % N % References References
Data requirement challenges
1. Treatment effectiveness 8 73 8 89 10 77 1 100 5 71 32 80 [2, 11, 57]
2. Prevalence 2 18 NA NA NA NA NA NA 3 43 5 31 [2, 57]
3. Accuracy data 5 45 NA NA NA NA NA NA 4 57 9 56 [2, 42, 57]
4. Compliancea 3 27 1 11 5 38 1 100 1 14 11 37 [2, 43, 57] [44]
5. Quality of life 7 64 8 89 7 54 0 0 3 43 24 71 [2, 57]
6. Resource use 6 55 7 78 7 54 1 100 3 43 24 60 [2, 57]
7. Unit costs 6 55 5 56 9 69 0 0 4 57 23 56 [2, 57]
8. Indirect costs 1 9 1 11 0 0 0 0 0 0 2 5 [58]
9. Missing values 1 9 4 44 0 0 0 0 0 0 5 13 [59]
10. Parameter distributions 4 36 4 44 3 23 1 100 2 29 14 35 [2, 57, 60]
11. Adverse events 5 45 6 67 6 46 0 0 1 14 18 45
12. Subpopulation data 4 36 1 11 2 15 0 0 2 29 8 20 [23]
13. Evidence synthesis 1 9 3 33 5 38 0 0 1 14 10 25 [1, 3, 6, 13] [61]
Modelling challenges
1. Structure 3 27 4 44 3 23 0 0 4 57 13 32 [21, 22]
1a. Comparators 3 27 3 33 0 0 0 0 0 0 6 15 [2, 13] [20, 62]
1b. Disease pathway 2 18 2 22 0 0 0 0 2 29 6 15 [1, 63] [64]
1c. Time horizon 0 0 1 11 1 8 0 0 0 0 2 5 [2, 3, 65] [66]
2. Heterogeneity 2 18 0 0 2 15 0 0 0 0 4 10 [23, 57]
3. History 0 0 0 0 0 0 0 0 0 0 0 0 [2]
4. Extrapolating short/
intermediate results
7 64 7 78 7 54 1 100 4 57 26 65 [2] [24]
5. Competing risks 2 18 0 0 1 8 0 0 0 0 3 8 [27] [28]
6. Multiple testing 3 27 0 0 NA 0 NA 0 2 29 5 31 [39, 40]
7. Multiple interventions
effects
0 0 1 11 0 0 0 0 2 29 3 8 [54]
8. Learning curve 2 18 0 0 NA NA NA NA 0 0 2 8 [34] [35]
9. Wait time (e.g. capacity
constraints)
0 0 2 22 NA NA NA NA 0 0 2 8 [67] [36]
10. Multiple indications 0 0 0 0 0 0 0 0 1 14 1 3 [33]
11. Lead time 0 0 NA NA 0 0 0 0 0 0 0 0 [49]
12. Reusability NA NA 0 0 NA NA NA NA NA NA 0 0 [48]
13. Process utilities NA NA 0 0 NA NA NA NA NA NA 0 0 [48]
14. Scenario analyses 0 0 0 0 0 0 0 0 0 0 0 0
DMP disease management programme, NA not applicable
The proportions were calculated based on the number of studies that could have been exposed to the challenges
a Compliance in studies that evaluate test interventions applies to the drug treatment, which is part of the strategy
b One study investigated two types of interventions (drug and non-drug interventions)
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meta-analysis. Bojke et al. [21] discussed ways (model
averaging, model selection and parameterizing structural
uncertainty) to address structural uncertainty. Frederix
et al. [22] have explored the influence of model structures
in breast cancer treatment on the estimated cost effective-
ness of an intervention.
3.2.3 Patient Heterogeneity
The difficulty of incorporating patient heterogeneity is
reported in some of the papers. Sufficient incorporation of
heterogeneity in a model requires a great deal of data that is
often not available. Recently, a review by Grutters et al.
[23] provided a comprehensive overview of the current
knowledge regarding patient heterogeneity within eco-
nomic evaluations of healthcare programmes, and provided
guidance for researchers to address heterogeneity.
3.2.4 Extrapolation of Short- or Intermediate-Term
Results
Modelling guidelines recommend that models should include
long-term or final outcomes [2]. One common problem in
modelling is that the length of follow-up of a clinical study used
in the model is shorter than the time horizon of the model.
Another problem is the fact that only intermediate outcomes
(e.g. sensitivity and specificity of coronary angiography or
surrogate outcomes (e.g. the effect of statins on low-density
lipoprotein [LDL] cholesterol) are presented. Methods to
extrapolate intermediate and surrogate outcomes are: (1) using
population-level data (e.g. national mortality statistics); (2)
long-term epidemiological (observational) studies or registries
that reflect the natural history of disease; (3) extrapolating
survival curves; and (4) assuming different scenarios for
extrapolation (based on, for example, expert opinion). A
common approach in CVD is to use trial-based results (short-
term) and extrapolate them by using literature or assuming
different scenarios for extrapolation. Furthermore, final out-
comes (lifetime costs or survival) of previously published
models that focus on a later stage in disease progression can be
used. For example, Lieu et al. [24] used published results from a
modelling study to estimate the cost effectiveness of primary
angioplasty. In addition, a CEA evaluating new-generation
computed tomography (CT) scanners for the diagnosis of
coronary artery disease (CAD) combined five existing models
to extrapolate test outcomes [25]. However, combining exist-
ing models introduces additional uncertainty since these are
often designed for different populations/interventions [26].
3.2.5 Competing Risks
Some studies (8 %) recognized the challenge of competing
risks (events that preclude or alter the likelihood of another
event occurring [4]. The paper of Putter et al. [27] reviewed
statistical methods for the analysis of competing risks and
how to model them. Wolbers et al. [28] has considered
three models to account for competing risks in risk pre-
diction models for coronary heart disease.
3.2.6 Multiple Intervention Effects
Some treatment strategies consist of multiple interventions
and some single interventions have an effect on more than
one clinical outcome. Estimating the effectiveness of such
interventions could be a challenge. It is more likely that
CEAs evaluating public health interventions or DMPs have
more difficulty in estimating the effectiveness since they
often exist of multiple interventions. This challenge can
also arise when estimating the cost effectiveness of life-
style interventions or drug interventions such as the ‘poly
pill’ that combines several pills (e.g. statins, aspirin, blood
pressure lowering drugs, folic acid) [29]. It is important to
recognize the problem of interrelating outcomes and
overestimation of the ‘real’ treatment effect. Interrelating
outcomes are present if an intervention (e.g. cardiovascular
DMP) has an effect on multiple outcomes (e.g. blood
pressure and smoking) which interact in some way to
improve health. When it comes to primary CVD preven-
tion, the Framingham risk score [30] or the Systematic
COronary Risk Evaluation (SCORE) risk function [31] are
often used to overcome the problem of interrelating out-
comes. Both risk functions estimate the risk of developing
a (non-) fatal event in the coming 10 years based on several
risk factors (e.g. smoking, cholesterol or age). While none
of the included studies consisted of multiple interventions,
some of them recognized that their single intervention
could have an effect on more than one clinical outcome.
When treatment effectiveness of such a strategy is lacking,
it is possible to use a synergy factor. Van Kempen et al.
[32] multiplied the individual relative risks of the single
interventions (aspirin and statins) and multiplied this with a
synergy factor. This factor can be varied through sensitivity
analyses, and incorporates the interaction between drugs
(synergy or dyssynergy).
3.2.7 Learning Curve
Obtaining effectiveness evidence of new tests and other
non-drug interventions (e.g. endovascular aneurysm repair
vs. open aneurysm repair) is often difficult due to the
presence of a learning curve [33]. It is important to include
the consequences of learning effects for new (invasive)
procedures. Learning effects could influence operating time
of a procedure, diagnostic accuracy, and the frequency of
adverse events. Ramsay et al. [34] presented statistical
techniques to incorporate learning effects of tests and
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procedures but concluded that new statistical techniques
should be developed. The impact of incorporating a learning
curve on the cost effectiveness of strategies will vary
depending on various factors. Woods et al. [35] investigated
the impact of the learning curve of heart transplantation on the
operative and postoperative hospital costs.
3.2.8 Waiting Time
In real life it is likely that tests and procedures are not
performed immediately after each other, sometimes
because of capacity issues. However, CEAs usually do not
incorporate capacity constraints and the time delay
between tests and procedures. Two papers identified wait-
ing time as a challenge [36, 37], and one of these examined
this issue in detail [36]. Neglecting waiting time may lead
to an overestimate of the effectiveness and cost effective-
ness of an intervention since a delay in assessment may
prolong suffering or increase the risk of cardiovascular
events (e.g. myocardial infarction or cardiac arrest). If
waiting time is deemed important, a disutility for the
quality-of-life loss due to postponed treatment can be
added. When the delay in treatment is due to capacity
constraints, then modelling guidelines suggest using an
agent-based simulation model or a discrete-event simulation
(DES) to incorporate competition for resources [2], as per-
formed by Jahn et al. [36] who evaluated the cost effectiveness
of drug-eluting stents versus bare-metal stents. A tree that
precedes a Markov model can also be used to include waiting
time from capacity constraints by modelling a proportion of
the cohort that suffers from these constraints.
3.2.9 Multiple Indications
Performing an economic evaluation of an intervention that
can be used for several indications is also considered a
challenge (3 %). Usually, interventions are evaluated for a
specific indication; however, many tests and drugs can be
used for several indications. Drugs are divisible and can be
evaluated for each indication separately and thus are not a
challenge per se. However, for example, the cost effec-
tiveness of a CT scanner in diagnosing CAD can be eval-
uated but this intervention can also be used in various
ways, such as brain CT scans. The weighted average of its
use in multiple applications can be used to estimate the
overall value of both costs and effects of the intervention
[33] in order to decide whether or not to purchase the
scanner. In order to estimate a weighted average of its use
for all applicants we need to know the relative frequency of
each application and have a sufficient understanding of the
alternative strategy, including the health and economic
consequences of correct and incorrect diagnoses. Further-
more, all effects would preferably be expressed using the
same unit of health gain (i.e. life-years or quality-adjusted
life-years).
3.2.10 Diagnostic Performance
Several authors (56 %) have indicated that it is a challenge
to obtain values for the diagnostic accuracy (sensitivity and
specificity) of a test. These input parameters to a model
usually have an important impact on the cost effectiveness
of the test since they are key in extrapolating an initial
disease status assessment, either being correct or incorrect
(false positive or false negative diagnosis). It is even more
of a challenge when tests are performed in combination or
sequence and previous test results need to be incorporated
in the model, as recognized by Denchev et al. [38]. It is a
challenge to estimate the sensitivity and specificity of each
individual test and of the whole strategy. It is very common
to assume that tests are independent; however, this does not
allow for already-known test results leading to misinter-
pretation of the test results (posterior probability) since the
interpretation of a test depends on the prior probability
(known test results and prevalence of outcome) and the
accuracy of the test. Hunink [39] explored the influence of
assuming independence for multiple test strategies. Wein-
traub et al. [40] examined the application of Bayes theorem
in non-invasive diagnosis of CAD and showed that it is not
always appropriate to assume independency. This chal-
lenge is mainly due to lack of data since it is almost
impossible to perform an observational diagnostic evalua-
tion study in order to derive reliable estimates of diag-
nostic, therapeutic and health status outcomes for multiple
test strategies [41]. Furthermore, estimates of the sensi-
tivity and specificity of a test (e.g. CT angiography) could
also be invalid since they are often derived by comparing
the result with a ‘gold standard’ (e.g. invasive coronary
angiography) which may not necessarily be 100 % accu-
rate [25]. When data is not available, the best strategy is to
vary the accuracy estimates in sensitivity analyses to esti-
mate the impact on cost effectiveness. However, the sen-
sitivity and specificity of a test might be linked, so that
improvements in one parameter may be achieved at the
expense of reductions in the other [42]. Berry et al. [42]
incorporated the link in a decision tree evaluating magnetic
resonance angiography. In addition, the ISPOR-SMDM
modelling guidelines recommend incorporating test results
that are prognostic in the states or as tracker variables in
state-transition models [3].
3.2.11 Compliance and Persistence
Compliance and persistence of interventions (e.g. drug
intervention or lifestyle interventions) is usually higher in
clinical trials than in daily practice due to close monitoring.
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Non-compliance can have an impact on medicine acqui-
sition costs and subsequent overall healthcare resource
utilization and costs [43]. However, non-compliance may
not always result in clinically meaningful differences
between efficacy and effectiveness due to long duration of
action in relation to its dosing interval (e.g. statins) [43].
Sokol et al. [44] investigated the impact of medication
adherence on hospitalization risk and healthcare costs for
four conditions: hypertension, diabetes, chronic heart fail-
ure and hypercholesterolemia. Drummond et al. [45] pro-
posed some suggestions for trials to become more
generalizable to a real-world situation. Guidelines on
compliance measurements are provided by Peterson et al.
[46]. While compliance could also be based on what is seen
during observational studies, these must be adjusted for
confounding through multivariate regression techniques or
propensity scoring [3]. If no ‘real’ estimates of compliance
are available, it could be useful to perform several scenario
analyses with different assumptions to estimate the impact
of compliance on cost effectiveness [47]. Ideally, these
scenarios should be based on expert opinion, partly to
determine how any observed short-term compliance rates
could be extrapolated. Modelling guidelines recommend
considering dynamic characteristics such as compliance in the
states or as tracker variables [6]. Hughes et al. [43] also rec-
ognized the challenge of incorporating compliance into
models, and provided some techniques to implement com-
pliance in decision models, DES models and Markov models.
3.2.12 Other Challenges
Other challenges not identified in the document analysis
but included in our survey are: (1) reusability; (2) lead time
bias; (3) incorporating history; (4) process utilities; and (5)
defining appropriate scenario analyses. Some interventions
such as telemonitoring devices for heart failure can be
reused in several patients and this element of reusability
might be incorporated in economic evaluations [48]. Lead-
time bias could be present in test interventions in the CVD
field [49] and should be considered in CEAs. Incorporating
history in a model may be a challenge and could be solved
by increasing the number of states in state-transition
models or modelling cost effectiveness with a DES model
[2]. Process utilities (ease, comfort of use or the unpleas-
antness of a device) could be a potential challenge,
although this was not identified in any of the studies
included in the document analysis.
3.3 Questionnaire
In total, six (15 %) corresponding authors completed and
returned the questionnaire after one reminder had been sent
to all corresponding authors and an additional reminder
sent to the authors who were initially willing to complete
the questionnaire. Of the six papers they had authored, two
focussed on drugs, two on tests, one on a population-based
strategy, and one on a device. These authors had previously
conducted an average of four CEAs of CVD interventions
using an economic model. The challenges found in the
document analysis were confirmed by the respondents; in
particular, lack of data and extrapolating short-term results.
However, the questionnaire also led to the identification of
challenges that were not described in the paper. For
example, one respondent indicated that extrapolation of
initial surrogate outcomes to later clinical events was a
challenge, even though this issue was not prominently
documented in the paper written by that author. This was
very likely because it was a methodological paper that
focussed on the impact of utilities on the incremental
effects [50].
4 Discussion
Model-based CEAs of CVD interventions are always
accompanied by challenges in modelling methods and data
requirements. This review identified and analysed the
challenges that currently exist in the CVD area. Further-
more, some ways to address the identified challenges based
on the literature and on expert opinion are mentioned.
Lack of effectiveness data and quality-of-life data,
determining a model structure, and extrapolating short- or
intermediate-term results, are very frequently reported or
implied challenges in the document analysis. However,
frequency is not necessarily an indicator of importance (i.e.
degree of impact on the ICER). Less-frequently reported
challenges are difficulties in incorporating patient hetero-
geneity and including waiting time for an intervention in
the model. The document analysis also showed that more
complex interventions are associated with more and more
complex challenges. Public health interventions, DMPs and
tests are interventions becoming more difficult to evaluate
since they combine several interventions (e.g. companion
diagnostic) instead of one single therapy. CVD interven-
tions have become more complex (including DMP, tar-
geted treatments and devices) over the years, meaning that
more parameters and relationships between parameters
have to be included in the analysis. Consequently, the
complexity of models has also increased over the years
[51]; for example, a simple decision tree is now used much
less often than before. Despite the increased complexity of
models, authors of the included studies did not report any
challenges that were impossible to be solved. One solution
that is often used to overcome challenges is the use of
sensitivity analysis. The influence of structural uncertainty
and patient heterogeneity on outcomes is less often
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assessed in model-based economic evaluations than
uncertainty regarding parameters and methodology.
4.1 Limitations
Since we limited our review by including only 40 papers in
a limited number of journals, the papers do not represent all
model-based CEAs of CVD interventions. However, we do
not expect the identified challenges identified using the
document analysis to differ substantially from those
reported in other papers since we have used the most recent
papers and those that were published in the most relevant
and highest impact journals.
The identification of challenges from papers is a sub-
jective process which may result in inconsistencies when
estimating their frequencies. However, we tried to elimi-
nate this subjectivity by having two reviewers score all
studies. Furthermore, the identification of challenges was
dependent on whether authors reported all of the challenges
they encountered in their study. Consequently, some of the
challenges actually encountered might not have been
identified by the reviewers and this might have led to an
underestimation of the frequencies. To identify challenges
that were not reported in the articles we sent the questionnaire
to the corresponding authors. However, the response rate was
15 % and therefore the usefulness of the questionnaire results
may be limited. For the responders, the questionnaire did
confirm the results of our own document analysis.
4.2 Recommendations
This review identified challenges that were present in
recently published model-based CEAs in the field of CVD.
However, most of these challenges and the ways to address
them could also be applied to interventions in other disease
areas. Challenges are often the result of data that is not
available, particularly relating to CEAs of test and non-
drug interventions. In our opinion, there are two main
reasons for this. First, the current regulatory framework in
the US and Europe for tests and non-drug interventions is
less stringent than for pharmaceuticals, i.e. the European
Medicines Agency does not require a randomized study
design for market approval, while the US FDA requires
only a single randomized controlled trial demonstrating
safety and effectiveness for high-risk tests or non-drug
interventions [48]. We recommend the regulations con-
cerning pharmaceuticals should also be applied to these
types of interventions since they are also subject to the
same budget constraints and should therefore meet the
same requirements for appraisal [48, 52]. Second, tests and
non-drug interventions are generally also associated with
clinical research-limiting factors such as the impossibility
of double blinding. We recommend that primary studies on
test and non-drug interventions should pursue rigid
research methods, as in drug efficacy studies.
We found that the validity of economic models con-
cerning the challenges and assumptions are often not
described in papers. However, if the validity of models is
described, this generally concerns face validity and tech-
nical validity (debugging) only, instead of disclosing how
challenges are addressed. We recommend authors report
their findings according to the Consolidated Health Eco-
nomic Evaluation Reporting Standards (CHEERS) state-
ment [53], making it easier to investigate the validity of the
model. While modellers are generally very resourceful
when it comes to overcoming challenges, one could
question whether those challenges are adequately addres-
sed since there are often many ways to do so. For instance,
Van Kempen et al. [54] showed that the use of different
methods to model the treatment effectiveness of statins
(through lipid-level modification, fixed risk reduction of
CVD events or risk reduction of CVD events proportional
to individual change in LDL cholesterol) led to different
results. Consequently, they also addressed the importance
of carefully considering the assumptions underlying a
simulation model and performing extensive model valida-
tion. As in the case of breast cancer modelling [55], we
recommend standardization of and better guidance for
disease-specific modelling in economic evaluations
5 Conclusions
Modelling is unavoidable when performing comprehensive
economic evaluations and always comes with challenges.
This study provides examples of CVD modelling chal-
lenges encountered during studies published in high-impact
journals. Some of the reported challenges are specific for
CVD, but most challenges are present in all types of dis-
eases. Modelling guidelines do not provide sufficient
assistance in resolving all challenges but it is probably
unrealistic to expect this. Besides identifying where more
research is needed, this review provides some directions for
researchers about how to deal with modelling challenges
when performing CEAs in the area of CVD.
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